Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC, Gutzmer R, Angela Y, Livingstone E, Lodde G, Meiss F, Rafei-Shamsabadi DA, Weyer-Fahlbusch SS, Nashan D, Loquai C, Hassel JC, Sachse MMM, Maul LV, Heinzerling L, Heppt MV, Colapietro C, Rusch J, Blome C. Kähler KC, et al. Among authors: gutzmer r. J Cancer Res Clin Oncol. 2024 May 14;150(5):252. doi: 10.1007/s00432-024-05713-6. J Cancer Res Clin Oncol. 2024. PMID: 38743104 Free PMC article.
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV. Pires da Silva I, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May 7;205:114101. doi: 10.1016/j.ejca.2024.114101. Online ahead of print. Eur J Cancer. 2024. PMID: 38735161
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. Schadendorf D, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Jun;204:114073. doi: 10.1016/j.ejca.2024.114073. Epub 2024 Apr 24. Eur J Cancer. 2024. PMID: 38723373 Free article. Clinical Trial.
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Ruf T, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May;203:114028. doi: 10.1016/j.ejca.2024.114028. Epub 2024 Mar 27. Eur J Cancer. 2024. PMID: 38652976 Free article.
Laudatio zum 80. Geburtstag von Prof. Dr. med. Wolfgang Tilgen.
Pföhler C, Ugurel S, Gutzmer R. Pföhler C, et al. Among authors: gutzmer r. J Dtsch Dermatol Ges. 2024 Apr;22(4):631-632. doi: 10.1111/ddg.15395_g. J Dtsch Dermatol Ges. 2024. PMID: 38574025 German. No abstract available.
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
Schaper-Gerhardt K, Gutzmer R, Angela Y, Zimmer L, Livingstone E, Schadendorf D, Hassel JC, Weishaupt C, Remes B, Kubat L, Spassova I, Becker JC. Schaper-Gerhardt K, et al. Among authors: gutzmer r. Eur J Cancer. 2024 May;202:113984. doi: 10.1016/j.ejca.2024.113984. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38479119 Free article.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Kennedy OJ, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. Eur J Cancer. 2024. PMID: 38402687 Clinical Trial.
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, Hassel JC, Berking C, Ziemer M, Nashan D, French LE, Vera J, Kerl-French KE, Gutzmer R, Heinzerling L. Kramer N, et al. Among authors: gutzmer r. J Eur Acad Dermatol Venereol. 2024 Feb 24. doi: 10.1111/jdv.19860. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38400651 No abstract available.
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E, Kowall B, Hassel JC, Schilling B, Sachse M, Gutzmer R, Loquai C, Kähler KC, Hüsing A, Gilde C, Thielmann CM, Zaremba-Montenari A, Placke JM, Gratsias E, Martaki A, Roesch A, Ugurel S, Schadendorf D, Livingstone E, Stang A, Zimmer L. Chorti E, et al. Among authors: gutzmer r. Eur J Cancer. 2024 Mar;200:113536. doi: 10.1016/j.ejca.2024.113536. Epub 2024 Jan 18. Eur J Cancer. 2024. PMID: 38306840 Free article.
401 results